Paradigm Biocapital Advisors LP Takes $17.29 Million Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

Paradigm Biocapital Advisors LP purchased a new position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 400,000 shares of the company's stock, valued at approximately $17,288,000. Scholar Rock comprises approximately 0.6% of Paradigm Biocapital Advisors LP's portfolio, making the stock its 26th largest holding. Paradigm Biocapital Advisors LP owned about 0.43% of Scholar Rock at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. GAMMA Investing LLC raised its position in Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Global Retirement Partners LLC grew its stake in Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after buying an additional 766 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after purchasing an additional 1,031 shares during the last quarter. Amalgamated Bank grew its stake in Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after purchasing an additional 620 shares during the last quarter. Finally, KBC Group NV purchased a new stake in Scholar Rock during the 4th quarter valued at about $131,000. 91.08% of the stock is owned by institutional investors.

Insider Transactions at Scholar Rock

In related news, insider Tracey Sacco sold 5,000 shares of the stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $32.83, for a total transaction of $164,150.00. Following the sale, the insider now owns 71,750 shares in the company, valued at $2,355,552.50. This represents a 6.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Edward H. Myles sold 142,292 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the completion of the sale, the chief financial officer now owns 111,345 shares in the company, valued at $3,966,108.90. The trade was a 56.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 255,231 shares of company stock worth $9,220,236 in the last ninety days. Insiders own 13.30% of the company's stock.

Scholar Rock Price Performance

Shares of Scholar Rock stock traded down $0.52 during trading on Monday, hitting $30.03. 386,670 shares of the company were exchanged, compared to its average volume of 1,267,417. The firm has a 50 day moving average price of $31.19 and a 200 day moving average price of $35.96. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $2.85 billion, a price-to-earnings ratio of -12.78 and a beta of 0.37. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter in the prior year, the business posted ($0.59) earnings per share. On average, equities analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wedbush reaffirmed an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a report on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.